TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02007863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transfusion
Description: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
Study: NCT04640987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
Study: NCT00665925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium (R935788)
Description: 100 mg tablet, orally, twice-a-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium (R935788)
Description: 150 mg tablet, orally, once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, either once a day, or twice a day
Study: NCT03591276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Drugs, Cancer
Description: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
Study: NCT03987295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: 60 mg/kg of AL001 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: 60 mg/kg of AL001 every 4 weeks
Study: NCT00393276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Combined hepatitis A and hepatitis B immunization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Combined hepatitis A and hepatitis B immunization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Combined hepatitis A and hepatitis B immunization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decavac
Description: Diphtheria and tetanus toxoid vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decavac
Description: Diphtheria and tetanus toxoid vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decavac
Description: Diphtheria and tetanus toxoid vaccine
Study: NCT01059058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MI Paste Plus
Description: A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PreviDent Fluoride Varnish
Description: A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Home Care
Description: Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Home Care
Description: Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Home Care
Description: Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
Study: NCT01628887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo Bilingual Breast Cancer Educational Intervention
Study: NCT00633022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOSMAPIMOD 7.5 MG
Description: GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOSMAPIMOD 7.5 MG
Description: GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
Study: NCT03546738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham spinal cord stimulation
Description: No spinal cord stimulation is provided

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham spinal cord stimulation
Description: No spinal cord stimulation is provided

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS implant
Description: a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead.
Study: NCT03085121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral resection in total knee arthroplasty
Description: EM and IM alignment systems are used to make the distal femoral cut in a random order.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal femoral resection in total knee arthroplasty
Description: EM and IM alignment systems are used to make the distal femoral cut in a random order.
Study: NCT03546738

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SCS implant
Description: a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead.
Study: NCT01685255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epacadostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Study: NCT00583999

Intervention type: OTHER
Intervention: no interventions, only regular blood-draw
Description: No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
Study: NCT01373515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: 4 bi-weekly vaccinations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: 4 bi-weekly vaccinations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: 4 bi-weekly vaccinations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: 4 bi-weekly vaccinations
Study: NCT03067987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.
Description: This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.
Description: This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~.
Study: NCT01140672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
Study: NCT03085121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral resection in total knee arthroplasty
Description: EM and IM alignment systems are used to make the distal femoral cut in a random order.
Study: NCT01140672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
Study: NCT03085121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal femoral resection in total knee arthroplasty
Description: EM and IM alignment systems are used to make the distal femoral cut in a random order.
Study: NCT04276818

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP group
Description: Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment group
Description: The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
Study: NCT03753971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound stimulation
Description: Short sound stimulations will be emitted through a head band during sleep apneas
Study: NCT00113698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo An inert preparation with similar appearance and taste to the drug
Study: NCT00026637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
Study: NCT00507026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Diclofenac
Description: IV Diclofenac q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketorolac
Description: IV ketorolac q6h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo q6h
Study: NCT05345912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-745 IV Solution
Description: CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-745 IV Solution
Description: CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-745 IV Solution
Description: CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-750 125mg capsule
Description: CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-750 125mg capsule
Description: CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-750 125mg capsule
Description: CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
Study: NCT03043365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCMUFA-rich saury oil
Description: 4 capsules, 3 times a day after meals
Study: NCT03987399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored educational intervention
Description: Educational day (lecture and workshop), clinical supervision and reminders
Study: NCT02830373

Intervention type: DEVICE
Intervention: LVIS stents
Description: Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
Study: NCT00095121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB)
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil (ADV)
Description: 10-mg tablet or 2-mg/mL oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamivudine
Description: 100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
Study: NCT03199092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRT+sat
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abilmente
Description: 'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
Study: NCT02207192

Intervention type: OTHER
Intervention: Postural change in lung volumes: sitting to Supine
Description: Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position.
Study: NCT00756977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI850
Description: multi-dose preparation for oral administration prior to colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350 based bowel preparation
Description: multi-dose preparation for oral administration prior to colonoscopy
Study: NCT03446547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg i.v. every fourth week for 12 months
Study: NCT02636790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery wait time
Description: VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery wait time
Description: VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
Study: NCT06096194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D-enhanced egg
Description: In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
Study: NCT02746679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
Study: NCT05345912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Placebo: 0.9 % normal saline
Description: IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Placebo: 0.9 % normal saline
Description: IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Placebo: 0.9 % normal saline
Description: IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
Study: NCT04454762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: oral administration (40 mg daily, reduced dose 20 mg daily)